Danish biotech UNION adds program to prevent COVID-19 with intranasal delivery of niclosamide.
· Niclosamide is a potent inhibitor of SARS-CoV-2 with potency >40x higher than remdesivir as demonstrated by Institut Pasteur Korea · The sinonasal cavity is considered a major site of early infection by SARS-CoV-2 and a major factor in transmission. · Intranasal administration of niclosamide has been demonstrated to prevent fatal outcomes in a murine challenge model · UNI91103 is a nasal spray pump delivering a concentrated niclosamide salt solution to the nasal cavity · UNI91103 has been tested in 44 healthy volunteers with positive results · UNI91103 is being prepared for